14-day Premium Trial Subscription Try For FreeTry Free
$1.50
+0.0100 (+0.671%)
At Close: Apr 24, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.24 $2.30 Wednesday, 24th Apr 2024 ATOS stock ended at $1.50. This is 0.671% more than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 7.77% from a day low at $1.48 to a day high of $1.60.
90 days $0.774 $2.30
52 weeks $0.590 $2.30

Historical Atossa Genetics Inc. prices

Date Open High Low Close Volume
Nov 29, 2023 $0.764 $0.780 $0.730 $0.730 289 183
Nov 28, 2023 $0.82 $0.83 $0.759 $0.778 272 403
Nov 27, 2023 $0.775 $0.83 $0.775 $0.81 380 149
Nov 24, 2023 $0.760 $0.80 $0.760 $0.790 126 870
Nov 22, 2023 $0.773 $0.791 $0.755 $0.769 221 832
Nov 21, 2023 $0.740 $0.790 $0.711 $0.771 681 011
Nov 20, 2023 $0.678 $0.740 $0.670 $0.740 384 458
Nov 17, 2023 $0.681 $0.681 $0.651 $0.680 207 294
Nov 16, 2023 $0.654 $0.689 $0.654 $0.680 157 617
Nov 15, 2023 $0.634 $0.665 $0.630 $0.654 354 230
Nov 14, 2023 $0.640 $0.664 $0.640 $0.641 223 733
Nov 13, 2023 $0.649 $0.670 $0.622 $0.631 333 548
Nov 10, 2023 $0.652 $0.679 $0.625 $0.635 353 362
Nov 09, 2023 $0.709 $0.709 $0.655 $0.663 338 877
Nov 08, 2023 $0.750 $0.750 $0.686 $0.709 224 759
Nov 07, 2023 $0.680 $0.777 $0.680 $0.740 598 054
Nov 06, 2023 $0.681 $0.710 $0.679 $0.680 242 391
Nov 03, 2023 $0.692 $0.736 $0.692 $0.700 276 696
Nov 02, 2023 $0.690 $0.715 $0.650 $0.698 729 470
Nov 01, 2023 $0.670 $0.686 $0.660 $0.675 174 617
Oct 31, 2023 $0.667 $0.677 $0.651 $0.670 156 128
Oct 30, 2023 $0.652 $0.678 $0.650 $0.654 231 718
Oct 27, 2023 $0.669 $0.680 $0.664 $0.669 134 697
Oct 26, 2023 $0.656 $0.680 $0.646 $0.672 306 103
Oct 25, 2023 $0.660 $0.680 $0.650 $0.658 174 458
Click to get the best stock tips daily for free!

About Atossa Genetics Inc.

Atossa Genetics Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien... ATOS Profile

Golden Star

Ticker Date Change Price
MLI Apr 19 10.86% $52.28
LPLA Apr 19 0.743% $262.59
DOOR Apr 18 0.160% $131.39
LNG Apr 17 0.389% $156.81
FCN Apr 16 2.95% $207.62
ELV Apr 16 5.28% $506.97
DXC Apr 08 0.767% $20.87
AKR Apr 05 5.63% $16.53
ITCI Apr 05 6.84% $68.44
SARK Mar 28 13.80% $26.88
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT